Introduction
Non-viral gene carriers can be viewed, in essence, as controlled release systems. Depending on the specific application, their function ranges from directing genes to the target tissue, enhancing or directing genes to nucleus of target cells, or controlling the DNA concentration in the local tissue. A gene delivery system for extracellular sustained release of plasmid DNA may prove valuable in gene medicine and genetic immunization applications. Such a polymeric gene delivery system could increase DNA bioavailability by both protecting DNA from nucleases and controlling the dispersion and retention of DNA in tissue, and offer the possibility of enhanced gene transfer efficiency and prolonged gene expression. Most widely studied DNA sustained release systems include encapsulation of DNA in biodegradable microspheres using polymers such as PLGA, 1 poly(lactide-co-phosphate). 4 The absorption of plasmids to the surface of cationic PLGA microparticles has been reported to achieve sustained release of plasmids. 5 Low DNA loading levels (Ͻ2%) and lack of versatility to control the DNA release kinetics are two parameters which remain to be optimized. Another advantage of the controlled release of DNA system is the ability of achieving localized gene delivery. An elegant example was recently reported by Klugherz et al 6 using a PLGA coating on to an expandable stent to achieve sustained DNA release for 10 days and yield positive gene expression in the coronary artery wall.
Here we examined the hypothesis that plasmid DNA condensed by a biodegradable polycationic gene carrier could be released in a sustained manner and such a complex system served as a depot of DNA to enhance the gene expression after intramuscular delivery. A biodegradable polyphosphoester, poly(2-aminoethyl propylene phosphate) (PPE-EA) was used to develop such a controlled release system for plasmid DNA. PPE-EA was a water soluble and biodegradable polyphosphoester with positive charged side chains (structure shown in Figure  1 ). 7 It was synthesized with a relatively high molecular weight (MW, 30 300, degree of polymerization: 100.2) to ensure the necessary hydrolytic stability to protect plasmid in physiological conditions. It was shown that, when PPE-EA was incubated in PBS at 37°C, its MW decreases 12% in 24 h, and declined gradually to 10 450 (65% decrease) after 7 days. PPE-EA readily formed complexes with DNA at various charge ratios. Complete binding of plasmid DNA by PPE-EA is achieved at charge ratios (N/P ratios) of 1 and above. Since PPE-EA degrades at an appreciable rate in a short period of time, these PPE-EA/DNA complexes could potentially achieve sustained release of plasmid DNA. In this study, we evaluated the tissue compatibility and cytotoxicity of PPE-EA, the protection effect of PPE-EA to DNA in the complexes and the release kinetics of DNA from the complexes. PPE-EAmediated gene delivery was demonstrated both in muscle gene expression of LacZ and in delivery of interferon␣2b to systemic circulation.
Results

Tissue response of PPE-EA in mouse muscle and its cytotoxicity
The cytotoxicity of PPE-EA was assessed in a cell culture assay using HEK293 cells. The assay was performed in comparison with the two most widely used polymeric gene carriers, poly-L-lysine (PLL, MW 27 kDa) and polyethylenimine (branched PEI, MW 25 kDa). The incubation period of cells with gene carriers was extended to 24 h as opposed to a typical 4-h incubation in order to highlight any potential toxic effect of PPE-EA. Cell viability was analyzed using the standard MTT method. In this assay, both PEI and PLL exhibited high toxicity to HEK 293 cells, with a LD 50 below 40 g/ml for PLL and 20 g/ml for PEI, respectively. In contrast, when cells cultured with PPE-EA at a dose of up to 100 g/ml, no statistically significant change in cell morphology and proliferation rate was observed compared with the control group (no polymer treatment) (Figure 2 ). Whereas at the same concentration, cells incubated with PLL and PEI only had a viability of below 20%. Similar results were observed when testing in COS-7 cells.
The acute tissue response to PPE-EA was evaluated in muscles in Balb/c mice, using saline and PEI injections as controls. PPE-EA and PEI were given at the same dose of positive charge (60 nmol of amino groups for PPE-EA and 60 nmol of total amino groups for PEI), to allow for a fair comparison with the assumption that the toxicity of these polymers predominantly stems from their cationicity. As a result, PPE-EA was given at a higher amount, 5.2-fold higher than PEI in mass (13.1 g of PPE-EA versus 2.5 g of PEI per injection). Histological analysis at day 7 revealed mild inflammatory reaction at muscle sites injected with the PPE-EA (Figure 3 ), whereas Gene Therapy severe inflammatory response was observed in the PEI group. Moreover, severe necrosis was noticeable in all the muscle samples receiving PEI injection, with a large amount of macrophages, histiocytes and neutrophils present at the injection sites.
PPE-EA protects plasmid DNA against serum and DNase I degradation
The protection effect of PPE-EA to DNA was demonstrated using serum containing medium and DNase I incubation. When incubated with 4 U/ml of DNase I at 37°C, naked DNA was almost completely degraded within 30 min (lane 4 of Figure 4a ). PPE-EA/DNA complexes (N/P, 2) subjected to the same DNase I treatment did not release any noticeable level of DNA (not shown). Lane 3 in Figure 4a showed a DNA sample recovered from freshly made complexes. DNA in complexes was recovered by a 0.8% SDS incubation overnight at 65°C, although a high degree of nicking occurred. Lane 2 of Figure 4a showed DNA recovered from complexes (N/P, 2) subjected to the same DNase I treatment, and it was comparable to lane 3, suggesting that the DNA in complexes survived the DNase I treatment.
The effect of serum on the DNA stability was also investigated (Figure 4b ). Naked DNA was significantly degraded after 1-h incubation with complete DMEM medium (containing 10% serum) at 37°C (lane 7 in Figure  4b versus lane 6), and complete degradation of DNA was observed after 2 h (lane 8, Figure 4b ). As a comparison, complexes (N/P, 2) were subjected to the same incubation with complete medium for 1 and 2 h, respectively, and the DNA samples recovered retained partial integrity as shown in lanes 9 and 10. The protection effect offered by complexes was more obvious for the 2-h incubation groups (lanes 8 versus 10). These results suggested that under physiological conditions, where the nuclease concentration is markedly lower than the test condition, such a formulation should significantly protect the plasmid.
Complexes yield sustained release of DNA as a result of PPE-EA degradation As stated earlier, PPE-EA underwent hydrolytic degradation at pH 7.4, and DNA in the complexes could be released from these complexes. Such complexes provided a controlled release system for plasmid DNA over a period of 2 weeks in PBS at 37°C. The release rate of DNA, measured by UV absorbance at 260 nm, was a function of charge ratio (Figure 5a ). When the complexes were prepared at a N/P ratio of 1, a burst release of 46% was observed for the first day, followed by about 4% release per day (24 g DNA/day/mg of complex) for 12 days. At a lower charge ratio of 0.5, only about 45% DNA was incorporated into the complexes. Nevertheless, the incorporated DNA was released at 15% for the first day and 0.9~4.8% (average of 1.95%) per day for the next 11 days. Higher charge ratios led to slower release of DNA from the complexes. At a N/P ratio of 1.5, no burst effect was observed, and DNA release followed first order release for the first week ( Figure 5b ) and then was nearly constant for the next week at a rate of 18 g DNA per day per mg of complexes. At a charge ratio of 2, DNA was released at a much slower rate, with an average of 45 g DNA per day per mg of complex for the first 4 days and then declined to 11 g DNA per day per mg of complex for the next 9 days.
DNA released from complexes retained partial bioactivity
The integrity of the DNA released from the complexes was assessed by gel electrophoresis. The gel retardation analysis (Figure 6a) showed that DNA released from the complexes remained intact, although a certain degree of nicking occurred at various time points. It was evident that complexes at higher N/P ratios substantially retarded the release of DNA. No DNA release was observed until day 5 for N/P ratio of 3, and none until day 7 for N/P ratio of 5. The difference in the integrity of DNA samples released from various complexes is negligible. Nevertheless, it is noted that the electrophoretic mobility of DNA released from the complexes was slightly lower than that of the original plasmid. This could be attributed to association of DNA with the degraded PPE-EA oligomers, as the samples were not purified and loaded directly for the electrophoresis.
The functional integrity of the released DNA sample was evaluated by their transfection activity in COS-7 cells using Transfast as a carrier. The DNA samples recovered from various complexes at days 3 and 7 were complexed with Transfast at a weight ratio of 2 for the transfection test. The transfection results shown in Figure 6b indicated that the DNA released from complexes prepared at different charge ratios had comparable transfection efficiency, although DNA samples recovered from complexes at day 7 yielded slightly lower transfection activity than the corresponding samples collected at day 3. These results suggested that PPE-EA could indeed deliver bioactive DNA in a sustained manner.
Gene Therapy
PPE-EA mediates higher gene expression in mouse muscle than naked DNA injection
The in vivo gene transfer efficiency of the PPE-EA/DNA complexes was evaluated in mouse muscle using LacZ as a model gene (Figure 7a ). The ␤-galactosidase expression levels in mice received complexes with N/P ratios of 0.5 and 1, respectively, were compared with those of naked DNA injection. At a dose of 2 g of DNA per muscle, naked DNA injection showed a peak expression of 280 pg of ␤-gal per muscle at day 3, and the expression leveled off at days 7 and 14. In contrast, PPE-EA/DNA complexes with an N/P ratio of 1 yielded a lower level of expression at day 3 (48 pg/muscle), peaked at 350 pg/muscle at day 7, and then decreased to 160 pg/muscle at day 14. This corresponded to 13-fold and six-fold higher gene expression than naked DNA expression at days 7 and 14, respectively. It is interesting to note that the complexes with a lower N/P ratio, 0.5 versus 1, were more effective. Complexes with an N/P ratio of 0.5 gave a 17-fold higher ␤-gal expression (465 pg/muscle) on day 7, and the level persisted until at least day 14. Unexpectedly the PPE-EA/DNA complexes with N/P ratios of 1.5 and 2 were ineffective. The enhancement effect of gene expression by PPE-EA was less pronounced at a higher DNA dose, showing similar kinetics with peak expression at day 7. Gene expression at day 7 after administering complexes (N/P, 0.5) at doses of 2, 10 and 25 g of DNA is shown in Figure 7b . At day 7 and a DNA dose of 10 g, ␤-gal expression mediated by PPE-EA/DNA complexes was five times higher than that of naked DNA, compared with 17-fold increase at 2-g DNA dose. At 25-g DNA dose, PPE-EA/DNA complexes yielded comparable levels of ␤-gal expression as achieved by naked DNA injection.
PPE-EA/DNA complexes delivers higher systemic level of interferon-␣2b than naked DNA
A plasmid encoding interferon-␣2b (IFN-␣2b) was used to test the effectiveness of PPE-EA as a carrier for the systemic delivery of secretory proteins via intramuscular injection. A single injection of PPE-EA/DNA complexes at a dose of 50 g of DNA was given to Balb/c mice, compared with naked DNA injection at the same dose. An N/P ratio of 0.5 was used because of the highest gene expression was achieved at this ratio in the ␤-gal expression study. The concentrations of IFN-␣2b in serum collected at different time points were analyzed by ELISA (Figure 8 ). No significant level of IFN-␣2b was detected in mice received 50 g of naked DNA injection until day 14, reaching 917 pg/ml and 790 pg/ml of IFN␣2b in serum on day 14 and 21, respectively. Compared with naked DNA injection, PPE-EA mediated gene transfer yielded a higher serum IFN-␣2b of 1.61 ng/ml on day 14 (P Ͻ 0.05), although IFN-␣2b concentration in serum declined to a similar level as naked DNA on day 21.
Discussion
The goal of this study was to develop a biocompatible and biodegradable gene carrier that could release the DNA in a sustained manner. The design of PPE-EA as a gene carrier had several folds of advantages. Firstly, the structure is built on a phosphate backbone with a 1,2-propylene diol moiety, and a charged aminoethyl side chain. The ultimate hydrolytic degradation products of this polymer are expected to be ␣-propylene glycol, phosphate and ethanolamine, all with minimal toxicity profiles. Such a design has led to a minimal toxicity profile of this polymer carrier, as demonstrated in the vigorous cytotoxicity assay, where gene carriers were incubated with cells for 24 h. The acute tissue response to PPE-EA evaluated in mouse muscles also revealed a similar contrast, when compared with PEI at a same dose of positive charges.
Secondly, PPE-EA had a relatively higher molecular weight compared with most other biodegradable gene carrier. [8] [9] [10] [11] [12] Its relatively high molecular weight of PPE-EA (MW, 30 300, degree of polymerization: 100.2) was achieved by ring opening polymerization. This feature coupled with the pedent chain charges increased the condensing ability of PPE-EA for DNA. Complete binding of DNA was achieved with PPE-EA at a charge ratio of 1, which was several-fold lower than other biodegradable gene carriers. At this charge ratio, PPE-EA was shown to effectively protect plasmid DNA from DNase I degradation and serum degradation.
On the other hand, the relatively high degradability of PPE-EA allowed the release of DNA in a sustained man-ner with the carrier degradation, despite strong binding between DNA and PPE-EA. DNA release occurred as early as a few hours at the low N/P ratios, to a few days of retardation for high N/P ratios. N/P ratio was the factor that dominated the kinetics of DNA release, especially in the first phase (within the first 6 days), during which period the DNA release rate decreased with the increase of N/P ratio. Such an adjustable DNA release kinetics is potentially advantageous in achieving different intracellular and extracellular sustained release of DNA. Nevertheless, the DNA release rate should be optimized for each particular application.
From the controlled release's point of view, these PPE-EA/DNA complexes offered obvious advantages compared with the other biodegradable polymer based systems, eg PLGA and polyanhydride micro/nanoparticles. Loading levels of DNA achieved in this system were much higher than those in PLGA microparticles. For example, PPE-EA/DNA complexes with a N/P ratio of 1 have a DNA payload of 60%, compared with less than 2% for PLGA or polyanhydride microspheres. The higher loading level reduced the use of carriers significantly. Moreover, the PPE-EA/DNA system was prepared by complex coacervation versus the double emulsion method for the microsphere systems. The former involved only aqueous conditions at room temperature, whereas the latter involved organic solvent and sonication/vortexing. The mild preparation conditions yielded good structural and functional integrity of the DNA released from PPE-EA/DNA complexes.
An obvious application of such a sustained gene delivery system was for intramuscular gene delivery. This has to be compared to naked DNA injection, which is somewhat effective in affording both local and systemic transgene expression. Despite obvious advantages, the appeal of naked DNA remains limited because of the relatively low level of gene expression. Intramuscular administration of PPE-EA/DNA complexes resulted in significantly higher and delayed ␤-gal expression in muscle, although the enhancement effect becomes less prominent at higher administration dose. The higher ␤-gal level in the PPE-EA mediated gene transfer is presumably due to the sustained release of plasmid at the injection site and the protection of plasmid by PPE-EA. An interesting point is that complexes prepared at lower N/P ratio (Ͻ1) achieved higher levels of gene expression, suggesting the complicated mechanism of gene delivery to skeletal muscle. What is surprising is that complex formulation at high N/P ratios such as 1.5 or 2 gave background level of gene expression in the muscle. This diminished gene expression was not likely due to any toxicity of PPE-EA in the complexes at higher N/P ratio, since the total amount of PPE-EA used in this formulation was only 20% of the dose tested for the tissue compatibility experiment. Muscle biopsy in these groups did not show any noticeable toxicity either. This is also consistent with the results from other cationic polymer/DNA complexes in muscle injection formulation, where no positive gene transfection has been reported. A recent study revealed that intramuscular injection of PEI/DNA complexes induces gene expression in the central nervous system (eg brain stem) through retrograde transport of the complexes/particles. 13 It is unclear yet if these PPE-EA/DNA complexes were transported out of the muscle in a similar manner.
Gene Therapy
This enhancement of gene expression could be applied to deliver therapeutic proteins to systemic circulation as demonstrated in the delivery of IFN-␣2b. This is a secretory protein that has a serum half-life of 1.7 h.
14 An N/P ratio of 0.5 has been selected due to its higher efficiency in the previous study. Following intramuscular injection, PPE-EA/DNA complexes generated 1.8 times higher IFN-␣2b in blood circulation than naked DNA on day 14 (P Ͻ 0.05), although at other time points, the expression levels were similar to those of naked DNA injection. This is particularly significant because of the short half-life of IFN-␣2b. It is worth noting that this result was obtained at a relatively higher dose of DNA (50 g). As suggested by the ␤-gal experiment, the enhancement effect by PPE-EA/DNA complexes might be more significant at lower doses.
We have investigated a variety of cationic carriers, including cationic liposomes and polymers, for in vivo gene delivery with no success in intramuscular injection route. In our hands, PPE-EA represented the first polymeric carrier that induces higher gene expression in muscle than naked DNA. Although the experimental protocol was far from optimized, these results suggested the potential of PPE-EA as a gene carrier for the local delivery, as well as systemic delivery of protein pharmaceutics.
Materials and methods
Materials N-(2-hydroxyethyl) carbamate and Pd/C (10%) were purchased from Aldrich Chemical (Milwaukee, WI, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from BDH Laboratory Supplies (Poole, UK). Poly-L-lysine (PLL, with an average molecular weight of 27 kDa), polyethylenimine (branched PEI, average molecular weight of 25 kDa), streptomycin and penicillin were purchased from Sigma (St Louis, MO, USA). PEI was purified by dialysis against water (dialysis tubing with MWCO 3500; Pierce, Rockford, IL, USA). Dulbecco's modified Eagle's medium (DMEM), L-glutamine, Terrific Broth and ampicillin were purchased from Gibco BRL (Grand Island, NY, USA). Fetal bovine serum (FBS) was the product of HyClone (Logan, UT, USA). QIAGEN Giga plasmid purification kit was purchased from Qiagen (Hilden, Germany). Luciferase assay system and Transfast transfection reagent were purchased from Promega (Madison, WI, USA). Bicinchoninic acid (BCA) protein assay kit was purchased from Pierce Chemical.
Plasmids pRELuc plasmid is a 11.9 kb pcDNA encoding firefly luciferase driven by a Rous sarcoma virus promoter inserted into an Invitrogen (San Diego, CA, USA) pREP7 vector (a gift from Dr RG Ulrich, NCI, Frederick, MD, USA). Plasmid p43-LacZ is a 7.9 kb pcDNA encoding ␤-galactosidase driven by AAV ITRs and CMV promoters (a gift from Dr B Bryne, University of Florida). Both plasmids were amplified in Escherichia coli DH5␣ and purified by QIAGEN Giga plasmid purification kit according to the manufacturer's protocol. The purified plasmids were dissolved in saline and kept in aliquots at a concentration of 1 to 2 mg/ml. pCMV-IVS-IFN-mod2 is a plasmid enco-ding human interferon-␣2b driven by a CMV promoter. It was kindly provided by The Immune Response Corporation (Carlsbad, CA, USA).
Synthesis and characterization of PPE-EA
PPE-EA was synthesized as reported earlier.
7 PPE-EA used in this study had a weight average molecular weight (MW) of 3.03 × 10 4 (standard deviation, 0.3%) and a number average molecular weight of 1.82 × 10 4 (standard deviation: 0.4%), as measured by gel permeation chromatography (GPC) using a Waters 2690 equipped with a Shodex Protein KW-804 column (Showa Denko KK, Tokyo, Japan), a multiangle light scattering detector (MiniDawn, Wyatt Technology, Santa Barbara, CA, USA) and a differential refractive index detector (Optilab DSP interferometric refractometer, Wyatt Technology). Phosphate buffer (0.1 M) with 0.15 M NaCl was used as the mobile phase at 0.5 ml/min flow rate (dn/dc = 0.075 ml/g).
Cell culture and animals
Monkey SV40 transformed kidney fibroblast COS-7 cells and human embryonic kidney 293 cells (HEK293) were obtained from ATCC, and maintained in DMEM supplemented with 10% FBS, L-glutamine (2 mM), streptomycin (100 g/ml), and penicillin (100 U/ml) at 37°C in a humidified 5% CO 2 -containing atmosphere.
Six-to 8-week-old female Balb/c mice were obtained and housed in National University of Singapore Animal Holding Unit. Mice were maintained on ad libitum rodent feed and water at room temperature, 40% humidity. All animal procedures were approved by the National University of Singapore Faculty of Medicine Animal Care and Use Committee.
Cytotoxicity of PPE-EA
The cytotoxicity of PPE-EA was evaluated in comparison with PLL and PEI. HEK 293 cells were seeded in a 96-well plate (Becton-Dickinson, Lincoln Park, NJ, USA) with 50 l of complete DMEM at a density of 20 000 cells per well. The cells were incubated for 24 h at 37°C followed by adding the solution of PPE-EA or PLL or PEI (50 l in complete DMEM) to achieve various carrier concentrations ranging from 0.01 to 1 mg/ml. Following 24-h incubation, 25 l of MTT solution (5 mg/ml in PBS) was added, and the plates were incubated at 37°C for an additional 2 h. To each well was added 100 l of the extraction buffer (20% SDS in 50% DMF) and the plate was incubated overnight at 37°C. The optical density at 570 nm in each well was measured on a microplate reader (Model 550, BioRad Laboratories, Hercules, CA, USA) using wells without MTT addition as the blank.
Tissue response of PPE-EA PPE-EA or PEI dissolved in saline (40 l) was injected into the tibialis anterior muscle in Balb/c mice at a dose equivalent to 60 nmol of positive charge (13.1 g/40 l for PPE-EA and 2.5 g/40 l for PEI). The muscles received the polymer injections were isolated at days 7, fixed in phosphate buffered formalin (10%), washed, and embedded in paraffin. Tissue sections were cut 8 m in thickness, placed on gelatin-coated slides, and stained with hematoxylin and eosin (H&E) for histological examination. The tissue response was evaluated by an independent pathologist. Mice receiving intramuscular injection of 40 l of saline were used as a control for this experiment.
Preparation of PPE-EA/DNA complexes and release of DNA from the complexes PPE-EA/DNA complexes were prepared in PBS with 1 mM EDTA by mixing pRELuc plasmid DNA (60 g/ml) with PPE-EA solution at concentrations ranging from 20 g/ml to 200 g/ml to achieve various charge ratios of 0.5 to 5. The complexes were incubated at room temperature for 30 min before use. Plasmid DNA release from the complexes was performed at 37°C. At various time points, complex samples were analyzed for plasmid integrity by gel electrophoresis (0.8% agarose gel). The amount of DNA released from the complexes was determined by measuring the optical density of supernatants at 260 nm after centrifugation at 10 000 g. Naked DNA incubated in the same buffer at 37°C was used as a control.
In vitro transfection activity of the released DNA Functional integrity of DNA samples released from the complexes at different charge ratios was evaluated by examining their transfection efficiency using a commercial liposome (Transfast) as a carrier. pRELuc DNA released from the complexes (with different N/P ratios) was complexed with Transfast according to the manufacturer's protocol, at a weight ratio of 2 in the releasing medium without purification. COS-7 cells were seeded 24 h before transfection into a 24-well plate (BectonDickinson) at a density of 3 × 10 4 cells/well with 1 ml of complete DMEM medium. At the time of transfection, the medium in each well was removed, washed with PBS, and replaced with 400 l of Opti-MEM, followed by adding the Transfast-DNA complexes containing 1 g of DNA. The transfection was performed at 37°C for 1 h, followed by adding 1 ml of fresh complete DMEM medium. After an additional 48-h incubation, cells were washed with PBS, permeabilized with 200 l of cell lysis buffer (Promega, Madison, WI, USA). The luciferase activity in cell extracts was measured for 10 s using a luciferase assay kit (Promega) on a luminometer (Lumat LB 9507, EG&G Berthold, Bad Wildbad, Germany). The light units (LU) were normalized against protein concentration in the cell extracts, which was measured using a BCA protein assay kit (Pierce).
DNase I protection assay PPE-EA/DNA complexes were prepared in saline at a charge ratio of 2 and incubated at 37°C with 5 l of DNase I solution (20 g/ml in 10 × reaction buffer, Roche Molecular Biochemicals, Mannheim, Germany) for 30 min. The samples were then mixed with 100 l of stop solution (400 mM NaCl, 100 mM EDTA, pH 8.0), followed by adding 12 l of 10% sodium dodecyl sulfate (SDS) and incubated at 65°C overnight. The mixtures were analyzed by gel electrophoresis (0.8% agarose) for the integrity of DNA. For the protection of plasmid in serum containing medium, complexes with a charge ratio of 5 were incubated with DMEM medium containing 10% fetal bovine serum for 1 to 2 h, and analyzed according to the same procedure.
␤-Galactosidase expression in mouse muscle
Balb/c mice (6 to 8 weeks old, three mice per group) received bilateral injections in the tibialis anterior muscle of p43-LacZ, or PPE-EA/p43-LacZ complexes prepared in saline (40 l) at different charge ratios (0.5 and 2.0) at a dose of 2, 10 or 25 g of DNA. A group of mice receiving the same volume of saline injection served as the background control. At days 1, 3, 7 and 14, the injected muscles were isolated and the expression level of ␤-galactosidase in the muscle was determined using a ␤-Gal Reporter Gene Assay kit (Roche Molecular Biochemicals). Briefly, the muscle was homogenized in 0.5 ml of lysis buffer with protease inhibitor supplied with the kit, and allowed to stand at room temperature for 30 min. The supernatant was collected after centrifugation, followed by a heat inactivation treatment of eukaryotic ␤-gal at 50°C for 60 min. An aliquot of 50 l of cell extracts was used to measure the light units for 10 s in Lumat LB 9507 (EG&G Berthold).
Delivery of interferon-␣2b using PPE-EA/DNA complexes pCMV-IVS-IFN-mod2 plasmid DNA was dissolved in saline at a concentration of 1.25 mg/ml. Complexes were prepared by adding 40 l of PPE-EA solution (0.41 mg/ml in saline) to 40 l of DNA solution containing 50 g DNA to achieve the N/P ratio of 0.5 and vortexed for about 20 s. The complexes were incubated at room temperature for 60 min. Balb/c mice (6 to 8 weeks old, five to seven mice per group) received bilateral injections in the tibialis anterior muscle of 40 l of complexes containing 25 g of DNA. One group of mice received bilateral injections of 25 g of plasmid DNA in 40 l of saline, and another group of mice receiving 40 l of saline was used as the background control. The mice were bled at days 6, 10, 14 and 21, and serum samples were isolated and stored at Ϫ80°C until assay. The concentrations of interferon-␣2b in serum at different time points were analyzed using a human IFN-␣ ELISA kit (Pierce Endogen, Woburn, MA, USA).
